Abstract:Objective: Transcription elongation factor 1 (TCERG1) is a nuclear protein consisted of multiple protein structural domains that plays an important role in regulating the transcription, extension, and splicing regulation of RNA polymerase II. However, the prognostic and immunological role of TCERG1 in human cancer remains unknown. In this study, we analyzed the expression of TCERG1 gene in hepatocellular carcinoma (HCC) patients, its clinical significance, and its possible prognostic value by bioinformatics. Methods: RNA sequencing data and clinicopathological characteristics of patients with HCC were collected from TCGA and CCLE databases. The Wilcoxon rank-sum test was used to analyze the expression of TCERG1 in HCC tissues and normal tissues. The protein levels of TCERG1 between normal and liver cancer tissues were analyzed by the Human Protein Atlas Database (HPA) (www.proteinatlas.org). Validation was performed using the Gene Expression Omnibus (GEO) dataset of 167 samples. The expression of TCERG1 in HCC cells were verified by qRT-PCR, and CCK-8, scratch assay and Transwell assay were performed to detect cell proliferation, migration and invasion ability. According to the median value of TCERG1 expression, patients were divided into high and low subgroups. Logistic regression, GSEA enrichment, TME, and single-sample set gene enrichment analysis (ssGSEA) were performed to explore the effects of TCERG1 on liver cancer biological function and immune infiltrates. TCERG1 co-expression networks were studied through the CCLE database and the LinkedOmics database to analyze genes that interact with TCERG1. Results: The expression levels of TCERG1 in HCC patient tissues were significantly higher than in normal tissues. Survival analysis showed that high levels of TCERG1 expression were significantly associated with low survival rates in HCC patients. Multifactorial analysis showed that high TCERG1 expression was an independent risk factor affecting tumor prognosis. This result was also verified in the GEO database. Cellular experiments demonstrated that cell proliferation, migration and invasion were inhibited after silencing of TCERG1 gene expression. Co-expression analysis revealed that CPSF6 and MAML1 expression were positively correlated with TCERG1. GSEA showed that in samples with high TCERG1 expression, relevant signaling pathways associated with cell cycle, apoptosis, pathways in cancer and enriched in known tumors included Wnt signaling pathway, Vegf signaling pathway, Notch signaling pathway, MAPK signaling pathway and MTOR pathways. The expression of TCERG1 was positively correlated with tumor immune infiltrating cells (T helper two cells, T helper cells). Conclusion: TCERG1 gene is highly expressed in hepatocellular carcinoma tissues, which is associated with the poor prognosis of liver cancer, and may be one of the markers for the diagnosis and screening of liver cancer and the prediction of prognosis effect. At the same time, TCERG1 may also become a new target for tumor immunotherapy.

GIT1 is a Novel Prognostic Biomarker and Facilitates Tumor Progression Via Activating ERK/MMP9 Signaling in Hepatocellular Carcinoma.

CHI3L1 Promotes Tumor Progression by Activating TGF-β Signaling Pathway in Hepatocellular Carcinoma.

Downregulation of AZGP1 by Ikaros and Histone Deacetylase Promotes Tumor Progression Through the PTEN/Akt and CD44s Pathways in Hepatocellular Carcinoma.

ITGB1 Drives Hepatocellular Carcinoma Progression by Modulating Cell Cycle Process Through PXN/YWHAZ/AKT Pathways

GJA1 Promotes Hepatocellular Carcinoma Progression by Mediating TGF-β-induced Activation and the Epithelial–mesenchymal Transition of Hepatic Stellate Cells

Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression.

The Overexpression of IQGAP1 and Β-Catenin is Associated with Tumor Progression in Hepatocellular Carcinoma in Vitro and in Vivo.

GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway

Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma

Expression and significance of the novel tumor-suppressor gene SMG-1 in hepatocellular carcinoma.

GINS1 promotes ZEB1‐mediated epithelial‐mesenchymal transition and tumor metastasis via β‐catenin signaling in hepatocellular carcinoma

Pan-cancer analysis and the oncogenic role of Glypican 1 in hepatocellular carcinoma

Overexpression of TCERG1 as a prognostic marker in hepatocellular carcinoma: A TCGA data-based analysis

Identifies Oncogene PDRG1 as a Potential Prognostic Biomarker in Hepatocellular Carcinoma: A Study Based on Bioinformatics Analysis

High GSTP1 inhibits cell proliferation by reducing Akt phosphorylation and is associated with a better prognosis in hepatocellular carcinoma.

TGM3 Promotes Epithelial-Mesenchymal Transition and Hepatocellular Carcinogenesis and Predicts Poor Prognosis for Patients after Curative Resection.

GBAP1 functions as a tumor promotor in hepatocellular carcinoma via the PI3K/AKT pathway

Inhibiting GIT1 Reduces the Growth, Invasion, and Angiogenesis of Osteosarcoma.

Prognostic Value of Matrix Metalloproteinase-1/ Proteinase-Activated Receptor-1 Signaling Axis in Hepatocellular Carcinoma.

High Expression of PIGC Predicts Unfavorable Survival in Hepatocellular Carcinoma

MAP Kinase-Interacting Kinase 1 Promotes Proliferation and Invasion of Hepatocellular Carcinoma and is an Unfavorable Prognostic Biomarker.